TY - JOUR
T1 - Effects of intranasal oxytocin in food intake and craving
T2 - A meta-analysis of clinical trials
AU - Chen, Chi Ying
AU - Chiang, Yu Chen
AU - Kuo, Tai Chih
AU - Tam, Ka Wai
AU - Loh, El Wui
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This study was supported by a grant provided the Taipei Medical University , Taipei, Taiwan, for newly employed teaching staff (TMU107-AE1-B05).
Publisher Copyright:
© 2021 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism
PY - 2021/10
Y1 - 2021/10
N2 - Objective: A rise of endogenous oxytocin (OT) is associated with anxiety and meal size reduction, and the effects of intranasal OT (INOT) have been examined in the management of food intake and craving. However, the discrepancy INOT effects in different disease populations are not entirely clear. Research design and methods: Updated systematic review and meta-analysis. By systematically searching the PubMed, Embase and Cochrane Library, we obtained 12 controlled trials. We performed meta-analyses to examine food intake, craving, anxiety or stress reduction on INOT administration, using standard mean difference (SMD) with a 95% confidence interval (CI) and a random-effects model. Results: This study examined 12 trials with 266 non-psychiatric and 157 psychiatric participants. The pooled results showed that single-dose INOT induced a significant lesser food intake in non-psychiatric subjects (SMD: −0.66 [95% CI: −1.18, −0.14]), but no effects was found in anorexia nervosa (AN) (SMD: 0.17 [95% CI: −0.32, 0.66]), bulimia nervosa (BN) and binge eating disorder (BED) (SMD: −0.41 [95% CI: −0.94, 0.11]), and schizophrenia (SMD: 0.04 [95% CI: −0.94, 1.02] subjects. Further analysis on leisure food also indicated an inhibition of consumption of chocolate biscuits in non-psychiatric subjects. Neither the non-psychiatric (SMD: −0.08 [95% CI: −0.50, 0.33]) nor the BN and BED (SMD: −0.08 [95% CI: −0.72, 0.88]) and schizophrenia subjects (SMD: −0.07 [95% CI: −1.05, 0.91]) demonstrated a difference in food craving or hunger compared with placebo. Anxiety or stress level was not influenced by INOT in any subgroup (non-psychiatric, SMD: 0.19 [95% CI: −0.22, 0.60]; AN, SMD: −0.01 [95% CI: −0.28, 0.88]; BN and BED: SMD: 0.00 [95% CI: −0.80, 0.80]). Conclusions: Single-dose INOT significantly reduces food intake in nonpsychiatric subjects, and further studies are necessary to assess the long-term effects and safety in obese patients. Whether INOT could be a treatment option for patients with eating disorders remains to be investigated.
AB - Objective: A rise of endogenous oxytocin (OT) is associated with anxiety and meal size reduction, and the effects of intranasal OT (INOT) have been examined in the management of food intake and craving. However, the discrepancy INOT effects in different disease populations are not entirely clear. Research design and methods: Updated systematic review and meta-analysis. By systematically searching the PubMed, Embase and Cochrane Library, we obtained 12 controlled trials. We performed meta-analyses to examine food intake, craving, anxiety or stress reduction on INOT administration, using standard mean difference (SMD) with a 95% confidence interval (CI) and a random-effects model. Results: This study examined 12 trials with 266 non-psychiatric and 157 psychiatric participants. The pooled results showed that single-dose INOT induced a significant lesser food intake in non-psychiatric subjects (SMD: −0.66 [95% CI: −1.18, −0.14]), but no effects was found in anorexia nervosa (AN) (SMD: 0.17 [95% CI: −0.32, 0.66]), bulimia nervosa (BN) and binge eating disorder (BED) (SMD: −0.41 [95% CI: −0.94, 0.11]), and schizophrenia (SMD: 0.04 [95% CI: −0.94, 1.02] subjects. Further analysis on leisure food also indicated an inhibition of consumption of chocolate biscuits in non-psychiatric subjects. Neither the non-psychiatric (SMD: −0.08 [95% CI: −0.50, 0.33]) nor the BN and BED (SMD: −0.08 [95% CI: −0.72, 0.88]) and schizophrenia subjects (SMD: −0.07 [95% CI: −1.05, 0.91]) demonstrated a difference in food craving or hunger compared with placebo. Anxiety or stress level was not influenced by INOT in any subgroup (non-psychiatric, SMD: 0.19 [95% CI: −0.22, 0.60]; AN, SMD: −0.01 [95% CI: −0.28, 0.88]; BN and BED: SMD: 0.00 [95% CI: −0.80, 0.80]). Conclusions: Single-dose INOT significantly reduces food intake in nonpsychiatric subjects, and further studies are necessary to assess the long-term effects and safety in obese patients. Whether INOT could be a treatment option for patients with eating disorders remains to be investigated.
KW - Anxiety
KW - Craving
KW - Food intake
KW - Intranasal oxytocin
KW - Oxytocin
KW - Stress
UR - http://www.scopus.com/inward/record.url?scp=85115961119&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115961119&partnerID=8YFLogxK
U2 - 10.1016/j.clnu.2021.08.011
DO - 10.1016/j.clnu.2021.08.011
M3 - Article
C2 - 34600216
AN - SCOPUS:85115961119
SN - 0261-5614
VL - 40
SP - 5407
EP - 5416
JO - Clinical Nutrition
JF - Clinical Nutrition
IS - 10
ER -